Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status : data from the Spanish SEMI-COVID-19 Registry
BACKGROUND: Hyperglycaemia has emerged as an important risk factor for death in coronavirus disease 2019 (COVID-19). The aim of this study was to evaluate the association between blood glucose (BG) levels and in-hospital mortality in non-critically patients hospitalized with COVID-19.
METHODS: This is a retrospective multi-centre study involving patients hospitalized in Spain. Patients were categorized into three groups according to admission BG levels: <140 mg/dL, 140-180 mg/dL and >180 mg/dL. The primary endpoint was all-cause in-hospital mortality.
RESULTS: Of the 11,312 patients, only 2128 (18.9%) had diabetes and 2289 (20.4%) died during hospitalization. The in-hospital mortality rates were 15.7% (<140 mg/dL), 33.7% (140-180 mg) and 41.1% (>180 mg/dL), p<.001. The cumulative probability of mortality was significantly higher in patients with hyperglycaemia compared to patients with normoglycaemia (log rank, p<.001), independently of pre-existing diabetes. Hyperglycaemia (after adjusting for age, diabetes, hypertension and other confounding factors) was an independent risk factor of mortality (BG >180 mg/dL: HR 1.50; 95% confidence interval (CI): 1.31-1.73) (BG 140-180 mg/dL; HR 1.48; 95%CI: 1.29-1.70). Hyperglycaemia was also associated with requirement for mechanical ventilation, intensive care unit (ICU) admission and mortality.
CONCLUSIONS: Admission hyperglycaemia is a strong predictor of all-cause mortality in non-critically hospitalized COVID-19 patients regardless of prior history of diabetes. KEY MESSAGE Admission hyperglycaemia is a stronger and independent risk factor for mortality in COVID-19. Screening for hyperglycaemia, in patients without diabetes, and early treatment of hyperglycaemia should be mandatory in the management of patients hospitalized with COVID-19. Admission hyperglycaemia should not be overlooked in all patients regardless prior history of diabetes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Annals of medicine - 53(2021), 1 vom: 11. Dez., Seite 103-116 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 12.11.2020 Date Revised 02.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/07853890.2020.1836566 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316330302 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316330302 | ||
| 003 | DE-627 | ||
| 005 | 20231225160841.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/07853890.2020.1836566 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316330302 | ||
| 035 | |a (NLM)33063540 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carrasco-Sánchez, Francisco Javier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status |b data from the Spanish SEMI-COVID-19 Registry |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.11.2020 | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Hyperglycaemia has emerged as an important risk factor for death in coronavirus disease 2019 (COVID-19). The aim of this study was to evaluate the association between blood glucose (BG) levels and in-hospital mortality in non-critically patients hospitalized with COVID-19 | ||
| 520 | |a METHODS: This is a retrospective multi-centre study involving patients hospitalized in Spain. Patients were categorized into three groups according to admission BG levels: <140 mg/dL, 140-180 mg/dL and >180 mg/dL. The primary endpoint was all-cause in-hospital mortality | ||
| 520 | |a RESULTS: Of the 11,312 patients, only 2128 (18.9%) had diabetes and 2289 (20.4%) died during hospitalization. The in-hospital mortality rates were 15.7% (<140 mg/dL), 33.7% (140-180 mg) and 41.1% (>180 mg/dL), p<.001. The cumulative probability of mortality was significantly higher in patients with hyperglycaemia compared to patients with normoglycaemia (log rank, p<.001), independently of pre-existing diabetes. Hyperglycaemia (after adjusting for age, diabetes, hypertension and other confounding factors) was an independent risk factor of mortality (BG >180 mg/dL: HR 1.50; 95% confidence interval (CI): 1.31-1.73) (BG 140-180 mg/dL; HR 1.48; 95%CI: 1.29-1.70). Hyperglycaemia was also associated with requirement for mechanical ventilation, intensive care unit (ICU) admission and mortality | ||
| 520 | |a CONCLUSIONS: Admission hyperglycaemia is a strong predictor of all-cause mortality in non-critically hospitalized COVID-19 patients regardless of prior history of diabetes. KEY MESSAGE Admission hyperglycaemia is a stronger and independent risk factor for mortality in COVID-19. Screening for hyperglycaemia, in patients without diabetes, and early treatment of hyperglycaemia should be mandatory in the management of patients hospitalized with COVID-19. Admission hyperglycaemia should not be overlooked in all patients regardless prior history of diabetes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a hyperglycaemia | |
| 650 | 4 | |a mortality | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 700 | 1 | |a López-Carmona, Mª Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Marcos, Francisco Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Belmonte, Luis M |e verfasserin |4 aut | |
| 700 | 1 | |a Hidalgo-Jiménez, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Buonaiuto, Verónica |e verfasserin |4 aut | |
| 700 | 1 | |a Suárez Fernández, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Freire Castro, Santiago Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Luordo, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Pesqueira Fontan, Paula Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Blázquez Encinar, Julio César |e verfasserin |4 aut | |
| 700 | 1 | |a Magallanes Gamboa, Jeffrey Oskar |e verfasserin |4 aut | |
| 700 | 1 | |a de la Peña Fernández, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Torres Peña, José David |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Solà, Joaquim |e verfasserin |4 aut | |
| 700 | 1 | |a Napal Lecumberri, Jose Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Amorós Martínez, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Guisado Espartero, María Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Jorge Ripper, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez Méndez, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Vicente López, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Román Bernal, Berta |e verfasserin |4 aut | |
| 700 | 1 | |a Rojano Rivero, María Gloria |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos Rincón, José Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez Huelgas, Ricardo |e verfasserin |4 aut | |
| 700 | 0 | |a SEMI-COVID-19 Network |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of medicine |d 1996 |g 53(2021), 1 vom: 11. Dez., Seite 103-116 |w (DE-627)NLM012634972 |x 1365-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2021 |g number:1 |g day:11 |g month:12 |g pages:103-116 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/07853890.2020.1836566 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2021 |e 1 |b 11 |c 12 |h 103-116 | ||